Abhijit Chakraborty
Overview
Explore the profile of Abhijit Chakraborty including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
112
Citations
2060
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Saha D, Dutta P, Rebello K, Shankar A, Chakraborty A
Mol Cell Biochem
. 2025 Mar;
PMID: 40045143
The increasing prevalence of early onset coronary artery disease (CAD) in individuals under 50 presents a significant public health challenge, with substantial impacts on quality of life and escalating healthcare...
2.
Turner J, Hinojosa-Gonzalez L, Sasaki T, Uchino S, Vouzas A, Soto M, et al.
bioRxiv
. 2025 Feb;
PMID: 39990485
Eukaryotic genomes replicate in a defined temporal order called the replication timing (RT) program. RT is developmentally regulated with potential to drive cell fate transitions, but mechanisms controlling RT remain...
3.
Fountzilas E, Pearce T, Baysal M, Chakraborty A, Tsimberidou A
NPJ Digit Med
. 2025 Jan;
8(1):75.
PMID: 39890986
The confluence of new technologies with artificial intelligence (AI) and machine learning (ML) analytical techniques is rapidly advancing the field of precision oncology, promising to improve diagnostic approaches and therapeutic...
4.
Fan D, Wang L, Chakraborty A, Zhang C, Yang F
Front Cardiovasc Med
. 2025 Jan;
11():1538222.
PMID: 39844902
No abstract available.
5.
Dozmorov M, Marshall M, Rashid N, Grible J, Valentine A, Olex A, et al.
Sci Rep
. 2024 Dec;
14(1):30519.
PMID: 39690151
No abstract available.
6.
Hoch M, Huth F, Manley P, Loisios-Konstantinidis I, Combes F, Li Y, et al.
Clin Pharmacokinet
. 2024 Oct;
63(11):1513-1528.
PMID: 39467980
Asciminib is a first-in-class allosteric inhibitor of the kinase activity of BCR::ABL1, specifically targeting the ABL myristoyl pocket (STAMP). This review focuses on the pharmacokinetic (PK) and pharmacodynamic data of...
7.
Valdez B, Tsimberidou A, Yuan B, Baysal M, Chakraborty A, Andersen C, et al.
Int J Mol Sci
. 2024 Sep;
25(17).
PMID: 39273190
Breast and ovarian cancers pose significant therapeutic challenges. We explored the synergistic cytotoxicity of histone deacetylase inhibitors (HDACis), poly(ADP-ribose) polymerase inhibitors (PARPis), and decitabine in breast (MDA-MB-231 and MCF-7) and...
8.
Baysal M, Chakraborty A, Tsimberidou A
J Cancer Immunol (Wilmington)
. 2024 Aug;
6(1):20-28.
PMID: 39119270
The emergence of chimeric antigen receptor T cell (CAR-T cell) therapy has revolutionized cancer treatment, particularly for hematologic malignancies. This commentary discusses developments in CAR-T cell therapy, focusing on the...
9.
Valdez B, Tsimberidou A, Yuan B, Nieto Y, Baysal M, Chakraborty A, et al.
Oncotarget
. 2024 Jun;
15:361-373.
PMID: 38829622
Histone deacetylase inhibitors (HDACi) can modulate the acetylation status of proteins, influencing the genomic instability exhibited by cancer cells. Poly (ADP ribose) polymerase (PARP) inhibitors (PARPi) have a direct effect...
10.
Torrado C, Baysal M, Chakraborty A, Norris B, Khawaja F, Tsimberidou A
Front Immunol
. 2024 May;
15:1366271.
PMID: 38779675
A patient in his 40s with splenic angiosarcoma metastatic to the liver underwent splenectomy, chemotherapy, and partial hepatectomy before being treated on a clinical trial with CTLA4 and PD1 inhibitors....